Core Viewpoint - Sangfor Biopharma (三生国健) has announced a collaboration with Pfizer for the development of project 707, a bispecific antibody targeting both PD-1 and VEGF, with potential uncertainties regarding milestone payments and royalties based on sales performance [1] Group 1 - Sangfor Biopharma's stock has experienced significant volatility, with a cumulative price deviation exceeding 30% over two trading days and 100% over four trading days, indicating abnormal trading activity [1] - The collaboration grants Pfizer exclusive rights to develop, produce, and commercialize the 707 project in regions outside mainland China for both human and veterinary applications [1] - The payment of milestone payments and royalties is contingent upon achieving specified sales targets, introducing uncertainty regarding the actual amounts received by the licensing parties [1] Group 2 - The sales performance of the licensed product may be influenced by various factors, including drug demand, market competition, and sales channels, contributing to the uncertainty surrounding the financial outcomes of the collaboration [1]

Group 1 - The core viewpoint of the article indicates that the company has a rolling price-to-earnings (P/E) ratio of 48.81, which is significantly higher than the industry average [1] - The company's stock has increased by over 100% since May 19, 2025, suggesting potential irrational speculation and a possible correction [1] - The company and its controlling shareholders do not have any undisclosed significant matters regarding the company, and its daily operations remain normal without major changes [1] Group 2 - There have been no significant adjustments in the industry policies affecting the company [1]

Market Overview - The Shanghai Composite Index fell by 0.22%, the Shenzhen Component Index decreased by 0.72%, and the ChiNext Index dropped by 0.96% on May 22, with a total market turnover of 1.1397 trillion yuan, a decrease of 74.6 billion yuan from the previous day [1] - Over 4,400 stocks closed in the red, while sectors such as military, banking, and gaming led the gains, whereas solid-state batteries and pet economy sectors saw declines [1] Stock Performance - A total of 40 stocks hit the daily limit up, with 13 stocks on consecutive limit up, and 27 stocks failed to close at the limit, resulting in a limit up rate of 60% (excluding ST and delisted stocks) [3] - Notable stocks included: - Sanofi's innovative drug concept stock, Sanofi Guojian, achieved a 20% limit up for four consecutive days [3] - Huibo Yuntong, involved in mergers and acquisitions, also reached a limit up for three consecutive days [3] Key Stocks and Transactions - Kunlun Wanwei saw a price increase of 20.01% to 37.43 yuan, with a turnover of 5.381 billion yuan and a turnover rate of 12.32% [4][5] - Zhongchao Holdings increased by 10.03% to 4.28 yuan, with a turnover of 744 million yuan and a turnover rate of 13.44% [12][13] - The top net purchases on the day were led by Kunlun Wanwei (339 million yuan), Zhongchao Holdings (210 million yuan), and Qingdao King (171 million yuan) [5] Institutional Activity - The top net selling stocks included Tianqimo (-2.83%), Hongbaoli (-8.60%), and Laisentongling (-10.02%) [6][20] - Institutional net purchases were significant in stocks like Kunlun Wanwei and Zhongchao Holdings, indicating strong interest from institutional investors [5][21] Sector Highlights - Kunlun Wanwei launched the "Skywork Super Agents," an AI agent architecture for multimodal content generation, which led to a surge in user engagement and subsequent stock performance [11] - Zhongchao Holdings is involved in military applications and low-altitude economy, with recent developments in high-temperature alloy precision casting for military aerospace components [14] - Zhongheng Electric, focusing on data center power and new power systems, reported a 111.05% increase in revenue from data center power business, contributing to overall revenue growth [19]

Core Viewpoint - Sanofi Health has reached a trading limit, with a transaction volume of 1.265 billion yuan and a turnover rate of 3.73% [1] Group 1 - The stock saw significant buying activity from the Shanghai-Hong Kong Stock Connect, with a net purchase of 72.1828 million yuan and a sale of 37.1571 million yuan [1] - Three institutional special seats recorded a net sell-off of 1.51 billion yuan [1] - There is an influx of dark pool funds into these stocks, indicating increased interest from institutional investors [1]

消息面上，据经济日报，当地时间5月20日，中国国家中医药管理局、马来西亚卫生部、尼泊尔卫生与 人口部、沙特阿拉伯卫生部、塞舌尔卫生部在瑞士日内瓦国际会议中心共同主办第78届世界卫生大会传 统医药边会。这是世界卫生组织成员国首次在大会期间举办以传统医药为主题的边会，旨在推动传统医 药融入各国卫生系统，更好服务全民健康覆盖和可持续发展目标，助力构建人类卫生健康共同体。 兴业证券表示，2025年需求有望迎来复苏，若经济基本面预期转好，消费医疗领域（医疗服务、中药 OTC与连锁药店等）基本面有望实现回升。同时，医疗器械2025年亦有望迎来改善。此外，AI医疗作 为科技方向，有望为医药产业带来新的变化，其产业趋势值得重视。 华源证券表示，展望2025年，我们认为医药板块已经具备多方面的积极发展因素，基本完成了新旧增长 动能转换（创新仿制，出海能力提升）。 5月22日，创新药概念震荡走强，上证科创板生物医药指数截至发稿涨0.10%，成分股中，三生国健冲 击20CM4连板，上海谊众、博瑞医药、英诺特、益方生物—U等跟涨。 相关ETF方面，科创医药指数ETF（588700）早盘震荡翻红，截至发稿涨0.20%，成交额超1500 ...

Core Viewpoint - On May 21, 2023, Sangfor Technologies (688336) closed at 47.24 CNY, reaching the daily limit up with a trading volume of 395 million CNY and a turnover rate of 1.37% [2] Trading Activity - The stock was listed on the daily trading leaderboard due to a price increase of 15% at the close [2] - The top five trading departments accounted for a total transaction of 255 million CNY, with a buying amount of 106 million CNY and a selling amount of 148 million CNY, resulting in a net sell of approximately 42 million CNY [2] - The third largest buying department was the Shanghai-Hong Kong Stock Connect, with a buying amount of 17.5 million CNY [2] - An institutional proprietary seat was noted among the selling departments, with a selling amount of 48.4 million CNY [2] Fund Flow - The stock experienced a net inflow of main funds amounting to approximately 5.6 million CNY on the same day [3] - The top buying departments included Guotai Junan Securities Beijing Financial Street with 52.1 million CNY and Aijian Securities Shanghai with 18.9 million CNY [3] - The top selling department was Tianfeng Securities Shanghai with 51.1 million CNY [3]

5月21日，三生国健（688336）再度冲上涨停，这已是公司连续第三个交易日涨停。连续多日涨停背后，是一则引爆创新药行业的重磅消息。 三生国健最新公告显示，三生国健及公司的关联方三生制药和沈阳三生制药有限责任公司（以下简称"沈阳三生"）共同授予被许可方辉瑞公司（Pfizer Inc.）（以下简称"辉瑞"）在许可区域（即除中国大陆以外的其他国家和地区）及领域（即人类和兽医用途的所有治疗、诊断及预防适应症）的独家开发、 生产和商业化许可产品707项目（即同时靶向PD-1和VEGF的双特异性抗体产品）的权利。 | 分时 | 5日 ~ | 5分钟 | 15分钟 | 30分钟 | 60分钟 日线 | 更多周期 · | | | 竟价 ▼ | 叠加· | 田 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | ◀ 股东大会：于2025-06-05召开2025年第二次临时股东大会 | | | | | | | | | | | | | | 三生国健 所属行业: 生物制品 最新:928.86 涨跌:+1.63% | ...

Investment Rating - The report maintains an "Overweight" rating for the company [5][8]. Core Views - The company has reached a significant licensing agreement with Pfizer for the 707 project, with potential upfront and milestone payments totaling up to $6.05 billion, of which the company will receive 30% [1][2]. - The 707 project shows promising clinical data and development progress, indicating strong potential for expanding indications and global commercialization [1][3]. - The company is expected to see a revenue surge due to licensing income, leading to an upward revision of profit forecasts for 2025-2027 [5][13]. Summary by Sections Licensing Agreement - The agreement with Pfizer includes an upfront payment of $1.25 billion and up to $4.8 billion in milestone payments, along with a double-digit percentage royalty on product sales [2][3]. Clinical Development - The 707 project has demonstrated excellent early clinical data, with an overall response rate (ORR) of 71% in first-line non-small cell lung cancer (NSCLC) and 33% in third-line colorectal cancer (CRC) [3]. - The project is currently in various stages of clinical trials, including Phase III for PD-L1+ NSCLC and Phase II for other indications [3]. Autoimmune Pipeline - The company has four late-stage autoimmune pipeline products expected to reach the market by 2026, with significant milestones anticipated in 2024 and 2025 [4]. - Early-stage products are also progressing, with potential for overseas licensing [4]. Financial Projections - The company’s revenue is projected to increase significantly, with estimates of RMB 4.08 billion in 2025, reflecting a 241.77% increase from previous estimates [7][13]. - The net profit attributable to the parent company is expected to reach RMB 2.94 billion in 2025, marking a substantial increase [7][13]. Valuation - The report assigns a target price of RMB 48.64, reflecting a valuation of RMB 30 billion based on comparable biotech companies [5][9].

Core Viewpoint - The recent performance of the STAR Market 100 Index and its ETF indicates a positive trend, with significant movements in individual stocks and a notable partnership between a Chinese pharmaceutical company and Pfizer [3][4][5]. Group 1: STAR Market 100 Index Performance - As of May 21, 2025, the STAR Market 100 Index rose by 0.21%, with notable increases in stocks such as Sangfor Technologies (19.99%) and Zai Lab (3.58%) [3]. - The STAR Market 100 Index ETF (588030) also increased by 0.21%, with a recent price of 0.97 yuan, and a one-month cumulative increase of 2.01% [3]. - The ETF's trading volume showed a turnover rate of 1.66%, with a total transaction value of 1.04 billion yuan [3]. Group 2: Fund Flows and Growth - The STAR Market 100 Index ETF experienced a net inflow of 2.30 billion yuan over the last five trading days, with an average daily net inflow of 459.57 million yuan [4]. - The ETF's recent financing net purchase reached 1.36 million yuan, with a total financing balance of 307 million yuan [5]. - The ETF's one-year net value increased by 18.03%, with a maximum monthly return of 27.67% since its inception [5]. Group 3: Strategic Partnerships - Recently, Sangfor Technologies and its subsidiaries entered into an exclusive licensing agreement with Pfizer, granting Pfizer global rights for a dual-specific antibody in China [3][4]. Group 4: Market Position and Trends - The Chinese innovative drug sector is expected to become a preferred choice for business development transactions due to its low R&D costs and high efficiency, positioning China as a center for low-cost R&D and production [4]. - The STAR Market 100 Index ETF closely tracks the STAR Market 100 Index, which consists of 100 medium-cap stocks with good liquidity from the STAR Market [4].

Group 1 - The Innovation Drug ETF (560900) increased by 1.60% with a turnover of 4.89% and a transaction volume of 1.6387 million yuan as of May 21, 2025 [1] - The CSI Innovation Drug Industry Index (931152) rose by 1.24%, with constituent stocks such as Sangfor Technologies (688336) up by 19.99%, Kanghong Pharmaceutical (002773) up by 6.38%, and Sinocelltech (688520) up by 6.23% [1] - As of May 20, the Innovation Drug ETF (560900) saw a year-to-date increase of 1 million shares, ranking among the top in terms of new share growth compared to similar funds [1] Group 2 - On May 20, Sangfor Technologies announced a licensing agreement with related parties Sangfor Pharmaceutical and Shenyang Sangfor, involving exclusive global development, production, and commercialization rights for a product with Pfizer, with an upfront payment of $1.25 billion and potential milestone payments of up to $4.8 billion [1] - The pharmaceutical and biotechnology industry is characterized by a resonance of innovation and domestic demand, with innovation being the core direction of the pharmaceutical sector according to Industrial Securities [1] Group 3 - The Innovation Drug ETF closely tracks the CSI Innovation Drug Industry Index, which selects up to 50 representative listed companies involved in innovative drug research and development to reflect the overall performance of the innovative drug industry [2] - Morgan Asset Management integrates its "Global Vision Investment Technology" product line to help investors layout quality technology companies globally, seizing investment opportunities amid the new wave of technology driven by AI [2] Group 4 - In passive investment, Morgan Hang Seng Technology ETF (QDII) provides a one-click layout for Hong Kong stock technology assets, while Morgan CSI Innovation Drug Industry ETF (560900) offers a one-click layout for Chinese innovative pharmaceutical companies [3] - Morgan NASDAQ 100 Index Fund (QDII) allows for a one-click investment in global technology leaders [3]